Search Results - A. Kaempf

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance by I. Khan, A. Kaempf, S. Raghuwanshi, M. Chesnokov, X. Zhang, Z. Wang, A. Domling, J. W. Tyner, C. Camacho, A. L. Gartel

    Published in Blood Cancer Journal (2023-08-01)
    Get full text
    Article


  2. 2

    P392: PHARMACOLOGICAL INHIBITION OF SYK CONFERS ANTI-PROLIFERATIVE AND NOVEL ANTI-TUMOR IMMUNE RESPONSES IN AML by L. A. Carvajal, B. Robinson, Y. Kosaka, T. Jacob, J. Lee, T. Hood, K. Baker, A. Kaempf, S. N.-A. Amara, J. Pucilowska, E. Lind, C. Tognon, J. Tyner, P. Kumar, T. Vu, J. DiMartino

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: